

OmniPathology and Delta Labs to expand access to Oropharyngeal HPV swab testing in Middle East

16 September 2025 | News

Company's innovative throat swab test for Oropharyngeal HPV is currently patent pending



OmniPathology, a US-based advanced molecular diagnostics laboratory, has announced a new international collaboration with Delta Medical Laboratories, a leading clinical laboratory provider in Saudi Arabia.

Under this agreement, Delta Labs will market and offer OmniPathology's proprietary and patent-pending swab test for oropharyngeal human papillomavirus (HPV) across Saudi Arabia and the broader Middle East region. Testing will be performed exclusively at OmniPathology's world-class laboratory in Pasadena, California.

This collaboration marks OmniPathology's first international partnership and represents a significant step toward expanding global access to its innovative molecular diagnostic testing.

Oropharyngeal HPV is increasingly recognized as a leading cause of head and neck cancers worldwide. Early detection through reliable molecular testing is critical for identifying at-risk patients and guiding clinical management. Globally, HPV is the most widespread sexually transmitted disease, according to the National Institutes of Health, and is the main cause of oropharyngeal and anogenital cancers.

This partnership represents the first phase of a long-term collaboration between OmniPathology and Delta Labs to bring specialized molecular testing services to international markets. Both organizations are exploring future opportunities for expanding their test portfolios and research collaborations to advance precision diagnostics worldwide.